Clovis Oncology Announces Proposed Secondary Offering Of Shares Of Common Stock By Selling Stockholders
Published: Dec 03, 2013
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that certain selling stockholders have commenced an underwritten public offering of 2,000,000 shares of the Company’s common stock which they recently acquired as consideration in connection with the Company’s acquisition of EOS (Ethical Oncology Science) S.p.A. All net proceeds from the sale of the common stock will be received by the selling stockholders. The Company will not receive any of the proceeds, and the total number of shares of its outstanding common stock will not change as a result of the offering.
Help employers find you! Check out all the jobs and post your resume.